Share of Collaboration and Royalty Revenue Related to Crysvita

Total Crysvita revenue was as follows (in millions):


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Product sales	$	54	$	35	$	100	$	90
Revenue in North American Territory:
Royalty revenue		67		55		94		84
Non-cash royalty revenue		27		24		39		36
Total revenue in North American Territory		94		79		133		120
Non-cash royalty revenue in European Territory		8		7		16		14
Total Crysvita revenue	$	156	$	121	$	249	$	224

Schedule of Cost Sharing Payments

These amounts were recognized in the Company’s Condensed Consolidated Statements of Operations in connection with the collaboration agreement with KKC as follows (in millions):


	Three Months Ended June 30,						Six Months Ended June 30,
	2026			2025			2026			2025
Research and development	$	(1	)	$	(1	)	$	(2	)	$	(2	)
Cost of sales		19			12			35			31

Schedule of Cost Sharing Payments


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Cost of sales	$	6	$	2	$	12	$	5